COVID-19 vaccination and prioritisation strategies in the EU/EEA
This document builds on a previously published ECDC report, ‘Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK’ . By using mathematical modelling, this document provides EU/EEA countries with information on factors that may affect the choice of COVID-19 vaccination
ECDC releases COVID-19 vaccination rollout strategies for EU/EEA
On 22 December ECDC released the technical report titled ‘COVID-19 vaccination and prioritisation strategies in the EU/EEA’, following the European Medicines Agency (EMA) recommendation for authorisation of the vaccine Comirnaty, developed by BioNTech and Pfizer.
Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK
This document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 vaccines in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK). The aim is to support but not define EU policy on COVID-19 vaccination.
Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, july 2017 to March 2018
Gossner, C.M., Haussig, J.M., de Bellegarde de Saint Lary, C., Kaasik Aaslav, K., Schlagenhauf, P., Sudre, B.
A network strategy to advance public health in Europe
Semenza, J.C., Apfel, F., Rose, T., Giesecke, J.
European Medicines Agency: Treatments and vaccines for COVID-19
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also making use of real-world data to monitor the safety and effectiveness of medicines used in patients with COVID-19.